Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis

8 October 2005

journal article
research article
Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases

Vol. 24 (10) , 688-690
https://doi.org/10.1007/s10096-005-0018-6

Abstract

In order to determine whether combination antibiotic therapy decreases mortality after severe pneumococcal infection, a retrospective study of a cohort of 1,840 adult patients with severe sepsis or septic shock enrolled in two multicenter clinical trials between 1994 and 1999 was conducted. Among 107 patients with monobacterial pneumococcal sepsis, the case-fatality rate was 20% (five of 25) for patients who received antibiotic monotherapy compared with 19.5% (16 of 82) for patients who received combination therapy (adjusted hazard ratio, 1.1; 95% CI, 0.4–3.1). Similarly, monotherapy did not increase the risk of death (adjusted hazard ratio, 1.0; 95% CI, 0.2–4.8) among bacteremic patients (n=75). However, the latter analysis may have been underpowered (power, 58%) to detect a difference in mortality. Overall, in contrast to recently published reports, these results suggest that combination antibiotic therapy does not decrease mortality after severe pneumococcal sepsis.

Keywords

This publication has 10 references indexed in Scilit:

Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal Bacteremia
American Journal of Respiratory and Critical Care Medicine, 2004
Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis
The American Journal of Medicine, 2003
Editorial Commentary: What is Optimal Antimicrobial Therapy for Bacteremic Pneumococcal Pneumonia?
Clinical Infectious Diseases, 2003
Addition of a Macrolide to a β‐Lactam–Based Empirical Antibiotic Regimen Is Associated with Lower In‐Hospital Mortality for Patients with Bacteremic Pneumococcal Pneumonia
Clinical Infectious Diseases, 2003
Monotherapy May Be Suboptimal for Severe Bacteremic Pneumococcal Pneumonia
Archives of internal medicine (1960), 2001
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients
Critical Care Medicine, 2001
Clinical Use of Ceftriaxone
Clinical Pharmacokinetics, 2001
Microbiologic Findings and Correlations with Serum Tumor Necrosis Factor–α in Patients with Severe Sepsis and Septic Shock
The Journal of Infectious Diseases, 1999
p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
1997
p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock
JAMA, 1997